This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
-
HonorHealth Research Institute, Scottsdale, Arizona, United States, 85258
City of Hope, Duarte, California, United States, 91010
Valkyrie Clinical Trials, Los Angeles, California, United States, 90067
University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California, United States, 92093
Sarcoma Oncology Center, Santa Monica, California, United States, 90403
University of Colorado Hospital, Aurora, Colorado, United States, 80045
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States, 30322
The University of Chicago, Chicago, Illinois, United States, 60637
Center for Cancer Research at NCI, Bethesda, Maryland, United States, 20892
University of Michigan, Ann Arbor, Michigan, United States, 48109
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to 85 Years
ALL
No
Inhibrx Biosciences, Inc,
Clinical Lead, STUDY_DIRECTOR, Inhibrx Biosciences, Inc
2026-07